mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2025-5-106-112mrj-1847Research ArticleОБЗОРЫREVIEWSСовременный взгляд на проблему резистентности к терапии при псориатическом артрите: обзор литературыCurrent view on therapy resistance in psoriatic arthritis: a literature reviewhttps://orcid.org/0000-0003-0579-1131КоротаеваТ. В.KorotaevaT. V.

Татьяна Викторовна Коротаева 

115522, Москва, Каширское шоссе, 34А 

Tatyana Viktorovna Korotaeva 

34A, Kashirskoe Shosse, Moscow 115522 

tatianakorotaeva@gmail.comhttps://orcid.org/0000-0001-6875-4552ЛогиноваЕ. Ю.LoginovaE. Yu.

115522, Москва, Каширское шоссе, 34А 

34A, Kashirskoe Shosse, Moscow 115522 

https://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34А 

125993, Москва, ул. Баррикадная, 2/1, стр. 1 

34A, Kashirskoe Shosse, Moscow 115522 

2/1, Barrikadnaya Street, Build. 1, Moscow 125993 

https://orcid.org/0000-0002-5044-5265КругловаЛ. С.KruglovaL. S.

121359, Москва, ул. Маршала Тимошенко, 19, стр. 1А 

19, Marshal Timoshenko Street, Build. 1A, Moscow 121359 

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» ; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology ; Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian FederationФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской ФедерацииРоссияCentral State Medical Academy of the Administration of the President of the Russian FederationRussian Federation202518102025195106112Copyright © Коротаева Т.В., Логинова Е.Ю., Лила А.М., Круглова Л.С., 20252025Коротаева Т.В., Логинова Е.Ю., Лила А.М., Круглова Л.С.Korotaeva T.V., Loginova E.Y., Lila A.M., Kruglova L.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1847

При псориатическом артрите (ПсА), несмотря на использование большего числа лекарственных средств, включая генно-инженерные биологические препараты (ГИБП), таргетные синтетические базисные противовоспалительные препараты, ремиссии и/или минимальной активности болезни достигает в среднем треть пациентов. Высокая клиническая гетерогенность ПсА и наличие сопутствующих заболеваний приводят к неоднократным переключениям ГИБП и способствуют формированию фармакорезистентности. В обзоре представлены современные данные о концепции и определении «трудно поддающегося лечению» ПсА (Difficult-to-Treat Psoriatic Arthritits, D2T PsA) и «сложного для ведения» ПсА (Complex-to-Manage Psoriatic Arthritits, C2M PsA), проанализированы факторы, ассоциированные с устойчивостью к лечению, рассмотрены перспективные терапевтические направления для этой категории пациентов.

Despite using a wide range of treatments, including biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs only about one third of patients with psoriatic arthritis (PsA) achieve remission and/or minimal disease activity. Marked clinical heterogeneity and frequent comorbidities lead to multiple biologics switching and contribute to pharmacoresistance. This review summarizes current concepts and definitions of “difficult-to-treat” PsA (D2T PsA) and “complex-to-manage” PsA (C2M PsA), analyzes factors associated with treatment resistance, and outlines promising therapeutic directions for this patient population.

резистентный к лечению псориатический артритсложный для ведения и трудно поддающийся лечению псориатический артритtreatment-resistant psoriatic arthritiscomplex-to-manage and difficult-to-treat psoriatic arthritisСтатья подготовлена в рамках государственного задания по теме № 125020501435-8 «Эволюция аксиальных спондилоартритов на основе комплексного динамического изучения молекулярно-биологических, молекулярно-генетических, клинико-визуализационных факторов прогрессирования заболевания, качества жизни, коморбидности и таргетной инновационной терапии».The article was prepared within the framework of the state assignment № 125020501435-8 “Evolution of axial spondyloarthritis based on comprehensive dynamic study of molecular-biological, molecular-genetic, clinical-imaging factors of disease progression, quality of life, comorbidities, and targeted innovative therapy.”ReferencesVeale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018 Jun 2;391(10136): 2273-2284. doi: 10.1016/S0140-6736(18)30830-4.Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018 Jun 2;391(10136): 2273-2284. doi: 10.1016/S0140-6736(18)30830-4.Schett G, Rahman P, Ritchlin C, et al. Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol. 2022 Jun;18(6): 311-325. doi: 10.1038/s41584-022-00776-6.Schett G, Rahman P, Ritchlin C, et al. Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol. 2022 Jun;18(6): 311-325. doi: 10.1038/s41584-022-00776-6.Ayan G, Ribeiro A, Macit B, Proft F. Pharmacologic treatment strategies in psoriatic arthritis. Clin Ther. 2023 Sep;45(9):826-840. doi: 10.1016/j.clinthera.2023.05.010.Ayan G, Ribeiro A, Macit B, Proft F. Pharmacologic treatment strategies in psoriatic arthritis. Clin Ther. 2023 Sep;45(9):826-840. doi: 10.1016/j.clinthera.2023.05.010.Корсакова ЮЛ, Коротаева ТВ, Логинова ЕЮ и др. Распространенность коморбидных и сопутствующих заболеваний при псориатическом артрите по данным Общероссийского регистра больных псориатическим артритом. Научно-практическая ревматология. 2021;59(3):275-281.Korsakova YuL, Korotaeva TV, Loginova EYu, et al. Prevalence of comorbid and concomitant diseases in psoriatic arthritis according to the All-Russian Registry of patients with psoriatic arthritis. Nauchno-prakticheskaya revmatologiya. 2021;59(3):275-281. (In Russ.).Lubrano E, Scriffignano S, Azuaga AB. Impact of comorbidities on disease activity, patient global assessment and function in Psoriatic Arthritis: A Cross-Sectional Study. Rheumatol Ther. 2020 Dec;7(4):825-836. doi: 10.1007/s40744-020-00229-0.Lubrano E, Scriffignano S, Azuaga AB. Impact of comorbidities on disease activity, patient global assessment and function in Psoriatic Arthritis: A Cross-Sectional Study. Rheumatol Ther. 2020 Dec;7(4):825-836. doi: 10.1007/s40744-020-00229-0.Логинова ЕЮ, Коротаева ТВ, Губарь ЕЕ и др. Трудный для лечения (difficult-to-treat) псориатический артрит. Данные Общероссийского регистра пациентов с псориатическим артритом. Современная ревматология. 2024;18(5):16-21. doi: 10.14412/1996-7012-2024-5-16-21Loginova EYu, Korotaeva TV, Gubar' EE, et al. Difficult-to-treat psoriatic arthritis. Data from the All-Russian registry of patients with psoriatic arthritis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2024;18(5):16-21. (In Russ.). doi: 10.14412/1996-7012-2024-5-16-21Sewerin P, Borchert K, Meise D, et al. Real-world treatment persistence with biologic disease-modifying antirheumatic drugs among German patients with psoriatic arthritis – a retrospective database study. Rheumatol Ther. 2021 Mar;8(1):483-497. doi: 10.1007/s40744-021-00286-z.Sewerin P, Borchert K, Meise D, et al. Real-world treatment persistence with biologic disease-modifying antirheumatic drugs among German patients with psoriatic arthritis – a retrospective database study. Rheumatol Ther. 2021 Mar;8(1):483-497. doi: 10.1007/s40744-021-00286-z.Насонов ЕЛ, Олюнин ЮА, Лила АМ. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научнопрактическая ревматология. 2018;56(3): 263-271.Nasonov EL, Olyunin YuA, Lila AM. Rheumatoid arthritis: problems of remission and resistance to therapy. Nauchno-prakticheskaya revmatologiya. 2018;56(3):263-271. (In Russ.).Gladman D, Chandran V, Rosen ChF, et al. Residual Disease Activity in Canadian patients with psoriatic arthritis treated with advanced therapies: results from a multiregistry analysis (UNISON-PsA). J Rheumatol. 2024 May 1;51(5):479-487. doi: 10.3899/jrheum.2023-0716.Gladman D, Chandran V, Rosen ChF, et al. Residual Disease Activity in Canadian patients with psoriatic arthritis treated with advanced therapies: results from a multiregistry analysis (UNISON-PsA). J Rheumatol. 2024 May 1;51(5):479-487. doi: 10.3899/jrheum.2023-0716.Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022 Mar;81(3): 359-369. doi: 10.1136/annrheumdis-2021-220991.Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022 Mar;81(3): 359-369. doi: 10.1136/annrheumdis-2021-220991.Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-712. doi: 10.1136/annrheumdis-2020-217159.Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-712. doi: 10.1136/annrheumdis-2020-217159.Glintborg B, Di Giuseppe D, Wallman JK, et al. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Ann Rheum Dis. 2023 Jun;82(6):820-828. doi: 10.1136/ard-2022-223650.Glintborg B, Di Giuseppe D, Wallman JK, et al. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Ann Rheum Dis. 2023 Jun;82(6):820-828. doi: 10.1136/ard-2022-223650.Simon D, Fagni F, Schett G. Sequential interleukin-17/interleukin-23 inhibition in treatment-refractory psoriatic arthritis. Ann Rheum Dis. 2022 Aug 11;81(9):1334-1336. doi: 10.1136/annrheumdis-2022-222415.Simon D, Fagni F, Schett G. Sequential interleukin-17/interleukin-23 inhibition in treatment-refractory psoriatic arthritis. Ann Rheum Dis. 2022 Aug 11;81(9):1334-1336. doi: 10.1136/annrheumdis-2022-222415.https://www.ajmc.com/view/fdaapproves-guselkumab-for-adult-patientswith-crohn-disease.https://www.ajmc.com/view/fdaapproves-guselkumab-for-adult-patientswith-crohn-disease.Leung YY, Kavanaugh A, Ritchlin CT. Expert perspective: management of the psoriatic arthritis patient after failure of one tumor necrosis factor inhibitor. Arthritis Rheumatol. 2023 Aug;75(8):1312-1324. doi: 10.1002/art.42498.Leung YY, Kavanaugh A, Ritchlin CT. Expert perspective: management of the psoriatic arthritis patient after failure of one tumor necrosis factor inhibitor. Arthritis Rheumatol. 2023 Aug;75(8):1312-1324. doi: 10.1002/art.42498.Eder L, Gladman DD, Mease P, et al. Sex differences in the efficacy, safety and persistence of patients with Psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension. RMD Open. 2023 Mar;9(1):e002718. doi: 10.1136/rmdopen-2022-002718.Eder L, Gladman DD, Mease P, et al. Sex differences in the efficacy, safety and persistence of patients with Psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension. RMD Open. 2023 Mar;9(1):e002718. doi: 10.1136/rmdopen-2022-002718.Tarannum S, Leung YY, Johnson SR, et al. Sex- and gender-related differences in psoriatic arthritis. Nat Rev Rheumatol. 2022 Sep; 18(9):513-526. doi: 10.1038/s41584-022-00810-7.Tarannum S, Leung YY, Johnson SR, et al. Sex- and gender-related differences in psoriatic arthritis. Nat Rev Rheumatol. 2022 Sep; 18(9):513-526. doi: 10.1038/s41584-022-00810-7.Ogdie A, Palmer JL, Greenberg J, et al. Predictors of achieving remission among patients with psoriatic arthritis initiating a Tumor Necrosis Factor inhibitor. J Rheumatol. 2019 May;46(5):475-482. doi: 10.3899/jrheum.171034.Ogdie A, Palmer JL, Greenberg J, et al. Predictors of achieving remission among patients with psoriatic arthritis initiating a Tumor Necrosis Factor inhibitor. J Rheumatol. 2019 May;46(5):475-482. doi: 10.3899/jrheum.171034.https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=a743da4e-2850-4edeb1b4-4b0ab1071e4bhttps://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=a743da4e-2850-4edeb1b4-4b0ab1071e4bLandgren AJ, Jonsson ChA, Bilberg A, et al. Sex differences in cytokines and adipokines in obese patients with PsA and controls undergoing a weight loss intervention. RMD Open. 2024 Mar 22;10(1):e003821. doi: 10.1136/rmdopen-2023-003821.Landgren AJ, Jonsson ChA, Bilberg A, et al. Sex differences in cytokines and adipokines in obese patients with PsA and controls undergoing a weight loss intervention. RMD Open. 2024 Mar 22;10(1):e003821. doi: 10.1136/rmdopen-2023-003821.Klingberg E, Björkman S, Eliasson B, et al. Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up. Arthritis Res Ther. 2020 Oct 22;22(1):254. doi: 10.1186/s13075-020-02350-5.Klingberg E, Björkman S, Eliasson B, et al. Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up. Arthritis Res Ther. 2020 Oct 22;22(1):254. doi: 10.1186/s13075-020-02350-5.Wong A, Ye JY, Cook RJ, et al. Depression and anxiety reduce the probability of achieving a state of sustained minimal disease activity in patients with psoriatic arthritis. Arthritis Care Res (Hoboken). 2025 Jul 1. doi: 10.1002/acr.25593. Online ahead of print.Wong A, Ye JY, Cook RJ, et al. Depression and anxiety reduce the probability of achieving a state of sustained minimal disease activity in patients with psoriatic arthritis. Arthritis Care Res (Hoboken). 2025 Jul 1. doi: 10.1002/acr.25593. Online ahead of print.Gordon KB, Armstrong AW, Han C, et al. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1940-1949. doi: 10.1111/jdv.15012.Gordon KB, Armstrong AW, Han C, et al. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1940-1949. doi: 10.1111/jdv.15012.Kerschbaumer A, Baker D, Smolen JS, et al. The effects of structural damage on functional disability in psoriatic arthritis. Ann Rheum Dis. 2017 Dec;76(12):2038-2045. doi: 10.1136/annrheumdis-2017-211433.Kerschbaumer A, Baker D, Smolen JS, et al. The effects of structural damage on functional disability in psoriatic arthritis. Ann Rheum Dis. 2017 Dec;76(12):2038-2045. doi: 10.1136/annrheumdis-2017-211433.Mease PhJ, Gottlieb AB, Ogdie A, et al Earlier clinical response predicts low rates of radiographic progression in biologic naпve patients with active psoriatic arthritis receiving guselkumab treatment. Clin Rheumatol. 2024 Jan;43(1):241-249. doi: 10.1007/s10067-023-06745-y.Mease PhJ, Gottlieb AB, Ogdie A, et al Earlier clinical response predicts low rates of radiographic progression in biologic naпve patients with active psoriatic arthritis receiving guselkumab treatment. Clin Rheumatol. 2024 Jan;43(1):241-249. doi: 10.1007/s10067-023-06745-y.Felten R, Duret PM, Gottenberg JE, et al. At the crossroads of gout and psoriatic arthritis: “psout”. Clin Rheumatol. 2020 May;39(5): 1405-1413. doi: 10.1007/s10067-020-04981-0.Felten R, Duret PM, Gottenberg JE, et al. At the crossroads of gout and psoriatic arthritis: “psout”. Clin Rheumatol. 2020 May;39(5): 1405-1413. doi: 10.1007/s10067-020-04981-0.Nagy G, Roodenrijs NMT, Welsing PMJ, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021 Jan;80(1):31-35. doi: 10.1136/annrheumdis-2020-217344.Nagy G, Roodenrijs NMT, Welsing PMJ, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021 Jan;80(1):31-35. doi: 10.1136/annrheumdis-2020-217344.Perrotta FM, Scriffignano S, Ciccia F, Lubrano E. Clinical Characteristics of Potential “Difficult-to-treat” Patients with Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort. Rheumatol Ther. 2022 Aug;9(4): 1193-1201. doi: 10.1007/s40744-022-00461-w.Perrotta FM, Scriffignano S, Ciccia F, Lubrano E. Clinical Characteristics of Potential “Difficult-to-treat” Patients with Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort. Rheumatol Ther. 2022 Aug;9(4): 1193-1201. doi: 10.1007/s40744-022-00461-w.Fagni F, Motta F, Schett G, Selmi C. Difficult-to-treat psoriatic arthritis: a conceptual approach. Arthritis Rheumatol. 2024 May;76(5): 670-674. doi: 10.1002/art.42780.Fagni F, Motta F, Schett G, Selmi C. Difficult-to-treat psoriatic arthritis: a conceptual approach. Arthritis Rheumatol. 2024 May;76(5): 670-674. doi: 10.1002/art.42780.Lubrano E, Scriffignano S, Perrotta FM. Difficult to treat and refractory to treatment in psoriatic arthritis. Rheumatol Ther. 2023 Oct;10(5):1119-1125. doi: 10.1007/s40744-023-00574-w.Lubrano E, Scriffignano S, Perrotta FM. Difficult to treat and refractory to treatment in psoriatic arthritis. Rheumatol Ther. 2023 Oct;10(5):1119-1125. doi: 10.1007/s40744-023-00574-w.Ribeiro AL, Dullius L, Sartori NS, et al. Challenges in the management of psoriatic arthritis in Latin America: a systematic review. Clin Ther. 2023 Sep;45(9):860-867. doi: 10.1016/j.clinthera.2023.04.005.Ribeiro AL, Dullius L, Sartori NS, et al. Challenges in the management of psoriatic arthritis in Latin America: a systematic review. Clin Ther. 2023 Sep;45(9):860-867. doi: 10.1016/j.clinthera.2023.04.005.Campanholo CB, Maharaj AB, Corp N, et al. Management of psoriatic arthritis in patients with comorbidities: an updated literature review informing the 2021 GRAPPA treatment recommendations. J Rheumatol. 2023 Mar;50(3):426-432. doi: 10.3899/jrheum.220310.Campanholo CB, Maharaj AB, Corp N, et al. Management of psoriatic arthritis in patients with comorbidities: an updated literature review informing the 2021 GRAPPA treatment recommendations. J Rheumatol. 2023 Mar;50(3):426-432. doi: 10.3899/jrheum.220310.Kumthekar A, Ashrafi M, Deodhar A. Difficult to treat psoriatic arthritis – how should we manage? Clin Rheumatol. 2023 Sep; 42(9):2251-2265. doi: 10.1007/s10067-023-06605-9.Kumthekar A, Ashrafi M, Deodhar A. Difficult to treat psoriatic arthritis – how should we manage? Clin Rheumatol. 2023 Sep; 42(9):2251-2265. doi: 10.1007/s10067-023-06605-9.Perrotta MF, Gentileschi S, Scriffignano S, et al. Difficult-to-Treat Concept in Psoriatic Arthritis: Analysis of 2 Potential Definitions in a Large Group of Patients: A Cross-Sectional Study. J Rheumatol. 2024 Oct 1;51(10): 985-990. doi: 10.3899/jrheum.2024-0101.Perrotta MF, Gentileschi S, Scriffignano S, et al. Difficult-to-Treat Concept in Psoriatic Arthritis: Analysis of 2 Potential Definitions in a Large Group of Patients: A Cross-Sectional Study. J Rheumatol. 2024 Oct 1;51(10): 985-990. doi: 10.3899/jrheum.2024-0101.Miyagawa I, Nakayamada S, Nakano K, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology (Oxford). 2019 Feb 1;58(2):336-344. doi: 10.1093/rheumatology/key069.Miyagawa I, Nakayamada S, Nakano K, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology (Oxford). 2019 Feb 1;58(2):336-344. doi: 10.1093/rheumatology/key069.Wirth T, Balandraud N, Boyer L, et al. Biomarkers in psoriatic arthritis: a metaanalysis and systematic review. Front Immunol. 2022 Nov 30:13:1054539. doi: 10.3389/fimmu.2022.1054539.Wirth T, Balandraud N, Boyer L, et al. Biomarkers in psoriatic arthritis: a metaanalysis and systematic review. Front Immunol. 2022 Nov 30:13:1054539. doi: 10.3389/fimmu.2022.1054539.Yuan Y, Qiu J, Lin ZT, et al. Identification of novel autoantibodies associated with psoriatic arthritis. Arthritis Rheumatol. 2019 Jun;71(6):941-951. doi: 10.1002/art.40830.Yuan Y, Qiu J, Lin ZT, et al. Identification of novel autoantibodies associated with psoriatic arthritis. Arthritis Rheumatol. 2019 Jun;71(6):941-951. doi: 10.1002/art.40830.Magee C, Jethwa H, FitzGerald OM, Jadon DR. Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review. Ther Adv Musculoskelet Dis. 2021 May 8:13:1759720X211014010. doi: 10.1177/1759720X211014010.Magee C, Jethwa H, FitzGerald OM, Jadon DR. Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review. Ther Adv Musculoskelet Dis. 2021 May 8:13:1759720X211014010. doi: 10.1177/1759720X211014010.Pournara E, Kormaksson M, Nash P, et al. Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. RMD Open. 2021 Nov;7(3): e001845. doi: 10.1136/rmdopen-2021-001845.Pournara E, Kormaksson M, Nash P, et al. Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. RMD Open. 2021 Nov;7(3): e001845. doi: 10.1136/rmdopen-2021-001845.Folle L, Bayat S, Kleyer A, et al. Advanced neural networks for classification of MRI in psoriatic arthritis, seronegative, and seropositive rheumatoid arthritis. Rheumatology (Oxford). 2022 Nov 28;61(12):4945-4951. doi: 10.1093/rheumatology/keac197.Folle L, Bayat S, Kleyer A, et al. Advanced neural networks for classification of MRI in psoriatic arthritis, seronegative, and seropositive rheumatoid arthritis. Rheumatology (Oxford). 2022 Nov 28;61(12):4945-4951. doi: 10.1093/rheumatology/keac197.https://www.asas-group.org/asas-definitionofdifficult-to-treat-axial-spondyloarthritis/https://www.asas-group.org/asas-definitionofdifficult-to-treat-axial-spondyloarthritis/Proft F, Ribeiro AL, Singla S, et al. OP0175 Establishing definitions for difficultto-treat psoriatic arthritis (D2T-PsA) and complex-to-manage psoriatic arthritis (C2MPsA): Insights from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) initiative. Ann Rheum Dis. 2025;84(Suppl 1):143-145. doi: 10.1136/annrheumdis-2025-eular.B3083.Proft F, Ribeiro AL, Singla S, et al. OP0175 Establishing definitions for difficultto-treat psoriatic arthritis (D2T-PsA) and complex-to-manage psoriatic arthritis (C2MPsA): Insights from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) initiative. Ann Rheum Dis. 2025;84(Suppl 1):143-145. doi: 10.1136/annrheumdis-2025-eular.B3083.

The authors declare that there are no conflicts of interest present.